Zobrazeno 1 - 10
of 12
pro vyhledávání: '"Annemarie M Leliveld"'
Autor:
Anne M May, Maike G Sweegers, Wim H Van Harten, Martijn M Stuiver, Alina Vrieling, Richard P Meijer, Antoine G van der Heijden, Wim G Groen, Emine Akdemir, Helene Rundqvist, Annemarie M Leliveld-Kors, Vera C Rutten, Evert L Koldewijn, Siebe D Bos, Carl J Wijburg, Tom A T Marcelissen, Bart C Bongers, Valesca P Retèl
Publikováno v:
BMJ Open, Vol 13, Iss 3 (2023)
Introduction Radical cystectomy (RC) is the standard treatment for patients with non-metastatic muscle-invasive bladder cancer, as well as for patients with therapy refractory high-risk non-muscle invasive bladder cancer. However, 50–65% of patient
Externí odkaz:
https://doaj.org/article/6898d199b52a41e6bfef5e52ecb207a2
Autor:
Jan-Willem H Dik, Ron eHendrix, Jerome R Lo-Ten-Foe, Kasper R Wilting, Prashant eNannan Panday, Lisette E van Gemert-Pijnen, Annemarie M Leliveld, Job evan der Palen, Alex W Friedrich, Bhanu eSinha
Publikováno v:
Frontiers in Microbiology, Vol 6 (2015)
Background: Antimicrobial resistance rates are increasing. This is, among others, caused by incorrect or inappropriate use of antimicrobials. To target this, a multidisciplinary Antimicrobial Stewardship-Team (A-Team) was implemented at the Universit
Externí odkaz:
https://doaj.org/article/1fe9317efda84da195159c63c14be6a8
Autor:
Adnan Aslan, Marius C. van den Heuvel, Coen A. Stegeman, Eliane R. Popa, Annemarie M. Leliveld, Grietje Molema, Jan G. Zijlstra, Jill Moser, Matijs van Meurs
Publikováno v:
Critical Care, Vol 22, Iss 1, Pp 1-12 (2018)
Abstract Purpose The histopathology of sepsis-associated acute kidney injury (AKI) in critically ill patients remains an understudied area. Previous studies have identified that acute tubular necrosis (ATN) is not the only driver of sepsis-AKI. The f
Externí odkaz:
https://doaj.org/article/c9be856239d0438abbfbe43fc28f8db8
Autor:
Claudine de Meijer, Dirk Wyndaele, Walter Noordzij, Pieter van den Berg, Agni Baka, Annemarie M. Leliveld-Kors, Joan van den Bosch, Michel L. Peters, Jennifer G. Gaultney
Publikováno v:
Applied Health Economics and Health Policy, 16(1), 133-143. Springer International Publishing AG
BACKGROUND: The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic c
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d1da47c8a3121b00462c6d95f44dc76c
https://doi.org/10.1007/s40258-017-0350-x
https://doi.org/10.1007/s40258-017-0350-x
Autor:
Gursah Kats-Ugurlu, Kim de Lange, Joost Hof, Martijn Terpstra, Paranita Ferronika, Annemarie M. Leliveld-Kors, Rolf H. Sijmons, Helga Westers, Klaas Kok
Publikováno v:
Cancers, 11(6):812. MDPI AG
Cancers
Volume 11
Issue 6
Cancers, Vol 11, Iss 6, p 812 (2019)
Cancers
Volume 11
Issue 6
Cancers, Vol 11, Iss 6, p 812 (2019)
While intratumour genetic heterogeneity of primary clear cell renal cell carcinoma (ccRCC) is well characterized, the genomic profiles of metastatic ccRCCs are seldom studied. We profiled the genomes and transcriptomes of a primary tumour and matched
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::908e58bf74f668fa4cafe8022e31d04b
https://research.rug.nl/en/publications/5330b91f-2738-402f-b7cd-a2eebf4e7969
https://research.rug.nl/en/publications/5330b91f-2738-402f-b7cd-a2eebf4e7969
Autor:
M. M. Terpstra, K. De lange, Rolf H. Sijmons, Paranita Ferronika, Annemarie M. Leliveld-Kors, Klaas Kok, Gursah Kats-Ugurlu, Joost Hof
Publikováno v:
Annals of Oncology, 28. Oxford University Press
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5a5a02950b64b37ac25fca8640970123
https://research.rug.nl/en/publications/2d09367b-ffe4-4a2e-9442-4c88f4ee2d25
https://research.rug.nl/en/publications/2d09367b-ffe4-4a2e-9442-4c88f4ee2d25
Autor:
Igle J. de Jong, Suzanne C van Es, Adrienne H. Brouwers, Elizabeth G. E. de Vries, Annemarie M. Leliveld-Kors, Marjolijn N. Lub-de Hooge, Shekar V. K. Mahesh, Jourik A. Gietema, Sjoukje F. Oosting
Publikováno v:
Journal of Nuclear Medicine, 58(6), 905-910. SOC NUCLEAR MEDICINE INC
Currently, biomarkers that predict the efficacy of everolimus in metastatic renal cell carcinoma (mRCC) patients are lacking. Everolimus inhibits vascular endothelial growth factor A (VEGF-A) expression. We performed PET scans on mRCC patients with 8
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8884d83225c5648e815c34c1401fecdd
https://research.rug.nl/en/publications/79de16a4-eea1-46c5-9300-d2705d87ce99
https://research.rug.nl/en/publications/79de16a4-eea1-46c5-9300-d2705d87ce99
Correction to: Dutch Economic Value of Radium-223 in Metastatic Castration-Resistant Prostate Cancer
Autor:
Dirk Wyndaele, Agni Baka, Jennifer G. Gaultney, Pieter van den Berg, Annemarie M. Leliveld-Kors, Michel L. Peters, Joan van den Bosch, Walter Noordzij, Claudine de Meijer
Publikováno v:
Applied Health Economics and Health Policy
Background The treatment of metastatic castration-resistant prostate cancer has changed with the introduction of radium-223, cabazitaxel, abiraterone and enzalutamide. To assess value for money, their cost effectiveness in patients with metastatic ca
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::4f7201cbbd160b47e6b2cd12b79208ce
http://europepmc.org/articles/PMC5797206
http://europepmc.org/articles/PMC5797206
Publikováno v:
European Journal of Cancer. 51:S179-S180
Background: The treatment landscape of metastatic castration resistant prostate cancer (mCRPC) has changed with the introduction of abiraterone acetate (AA), enzalutamide (EN) and radium-223 (Ra-223). Little is known about the cost-effectiveness of t
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::1af249d67c344d4c82738bf16aebd30a
https://doi.org/10.1016/s0959-8049(16)30527-5
https://doi.org/10.1016/s0959-8049(16)30527-5
Autor:
Rolf H. Sijmons, Harry Hollema, Annemarie M Leliveld, Jan H. Kleibeuker, Marian J.E. Mourits, Jan J. Koornstra
Publikováno v:
The Lancet. Oncology. 10(4)
Hereditary nonpolyposis colorectal cancer, or Lynch syndrome, is responsible for 2-3% of all colorectal cancers. Lynch syndrome is also associated with a high risk of extracolonic cancers, including endometrial, stomach, small bowel, pancreas, biliar
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::8776e0378716cca1001f5ad29ea7fa1c
https://pubmed.ncbi.nlm.nih.gov/19341971
https://pubmed.ncbi.nlm.nih.gov/19341971